NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...

The health ministry is expected to cut the official price of the drug by up to 15% from the current level of about ¥3 million ...

A promising new study from the Knight Family DIAN-TU research group at Washington University School of Medicine has found that starting Alzheimer’s treatment years before symptoms begin could delay — ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope. “Alzheimer’s disease is a specific condition resulting from an abnormal biological ...

TAMPA, Fla. — The Food and Drug Administration has granted accelerated approval to the experimental drug lecanemab, shown to slow down the progression of Alzheimer’s disease in its early ...

What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

With promising drugs in the pipeline, we are on the cusp of "turning the tide" against Alzheimer's. But President Trump's plan to slash research spending could delay or halt progress for years, ...

The New York Times ran a lengthy interview this morning between columnist Ross Douthat and venture capitalist and PayPal ...

Unfortunately, medical treatments for Alzheimer’s disease and dementia have remained minimal for over 25 years, and with a growing aging population, Alzheimer’s disease has be ...

A once-a-day pill called blarcamesine may slow memory loss and preserve independence—without the scary side effects or ...

Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients new hope through MUSC's SCAN program ...

To that end, he expressed his optimism for the future of Alzheimer’s treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval. "Both have proven to ...